Q-omics provides the consensus-scored FSHB profile across patient tissues and cancer cell-line models. FSHB expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, FSHB is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, FSHB RNA expression shows 6,315 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRC, and STAD as cancer lineages where FSHB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FSHB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FSHB survival associations across molecular data types. FSHB RNA expression shows survival associations in the most cancer types (12), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FSHB RNA expression–survival associations across cancer types. High FSHB expression shows unfavorable associations in SKCM, COAD, OV, ACC, STAD and KIRP. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for FSHB RNA expression.
This table summarizes FSHB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FSHB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FSHB shows lower tumor expression in KIRC, KIRP, KICH and THCA and higher tumor expression in PRAD. The KIRC box plot shows higher FSHB RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p < 0.001).
This table shows molecular features associated with FSHB in patient tissues and cancer cell lines. In patient samples, FSHB shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FSHB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LUNG_NSCLC_LUAD.
